The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a 35-year-old man who has suffered from ...

Using an early patient experience as a launching point, Miguel Regueiro, MD, reflects on the gradual shift away from treatments for ulcerative colitis, such as the long-term prescribing of ...

We randomly assigned patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1000 mg on day 1 and 500 ...